Bioline Says Pilot Study of Potential Pancreatic Cancer Drug Combo Shows Improved Overall Response Rate; Shares Soar Pre-Bell

MT Newswires Live
05/30

Bioline RX (BLRX) said Friday that results from a pilot phase 2 clinical trial of its drug motixafortide, along with cemiplimab and standard-of-care chemotherapies, as a first-line treatment for pancreatic cancer showed that four out of 11 patients remained progression-free after more than one year.

The study is evaluating the motixafortide combination against gemcitabine and nab-paclitaxel alone, the company said.

An analysis also revealed that tumor infiltration increased in all eleven patients treated with the motixafortide combination, the company said.

In all, the trial showed an overall response rate of 64% and a disease control rate of 91%, compared to historical rates of 23% and 48%, respectively, for gemcitabine and nab-paclitaxel, the company said.

The company said the trial will now increase enrollment in a randomized study to 108, from the previous 30, by 2027.

Shares of the company were up more than 64% in recent premarket activity.

Price: 6.25, Change: +2.46, Percent Change: +64.87

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10